scispace - formally typeset
R

Ramon Salazar

Researcher at University of Barcelona

Publications -  52
Citations -  5104

Ramon Salazar is an academic researcher from University of Barcelona. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 23, co-authored 45 publications receiving 4410 citations. Previous affiliations of Ramon Salazar include Carlos III Health Institute.

Papers
More filters
Journal ArticleDOI

Gastroenteropancreatic neuroendocrine tumours.

TL;DR: To improve outcome from GEP NETs, a better understanding of their biology is needed, with emphasis on molecular genetics and disease modeling, and more-reliable serum markers, better tumour localisation and identification of small lesions, and histological grading systems and classifications with prognostic application are needed.
Journal ArticleDOI

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

Martyn Caplin, +50 more
- 02 Feb 2015 - 
TL;DR: PCs are complex tumors which require a multidisciplinary approach and long-term follow-up, and may be considered as first-line systemic antiproliferative treatment in unresectable PCs, particularly of low-grade TC and AC.
Journal ArticleDOI

ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas

TL;DR: This poster presents a poster presented at the 2016 European Congress of Medical Oncology and Hepatology/Gastroenterology/Oncology Congress in Vienna, Austria, presenting the findings of a two-week clinical trial of positron emission tomography/computed Tomography/answers for the diagnosis of central giant cell granuloma.
Journal ArticleDOI

ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms

TL;DR: This research presents a meta-analyses of the immune system’s response to chemotherapy, which shows clear patterns of decline in the immune systems of patients with symptomatic oncologists and patients with a history of liver disease.